Reinfection Rates among Patients who Previously Tested Positive for COVID-19: a Retrospective Cohort Study
Preprint
Abstract
Objectives To evaluate reinfection rates and protective effectiveness of prior disease among patients with coronavirus disease 2019 (COVID-19) infection in the United States. Design Retrospective cohort study Setting One multi-hospital health system in Ohio and Florida Participants All 150,325 patients who were tested for COVID-19 infection via PCR from March 12, 2020 to August 30, 2020. Testing performed up to January 7, 2021 in these patients was included for analysis. Healthcare workers were excluded. Main outcome measures The main outcome was reinfection, defined as infection ≥ 90 days after initial testing. Secondary outcomes were symptomatic infection and protective effectiveness of prior infection. Results Of 150,325 patients tested for COVID-19 prior to August 30, 8,845 (5.9%) tested positive and 141,480 (94.1%) tested negative. 974 (11%) of the positive patients were retested after 90 days, and 56 had possible reinfection. Of those, 26 (46.4 %) were symptomatic. Of those with initial negative testing, 4,163 (12.9%) were subsequently positive and 2,460 of those (59.1%) were symptomatic. Protective effectiveness of prior infection was 78.5% (95% confidence interval 72.0 to 83.5), and against symptomatic infection was 83.1% (95% confidence interval 75.1 to 88.5). Protective effectiveness increased over time. Conclusions Prior infection in patients with COVID-19 was highly protective against reinfection and symptomatic disease. Protective effectiveness increased over time, suggesting that viral shedding or ongoing immune response may persist beyond 90 days and may not represent true reinfection. As vaccine supply is a limited resource around the world, patients with known history of COVID-19 could delay early vaccination to allow for the most vulnerable to access the vaccine and slow transmission.Keywords
All Related Versions
- Published version: Clinical Infectious Diseases, 73 (10), 1882.
This publication has 12 references indexed in Scilit:
- Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care WorkersNew England Journal of Medicine, 2021
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineNew England Journal of Medicine, 2021
- SARS-CoV-2 persistence is associated with antigen-specific CD8 T-cell responsesEBioMedicine, 2021
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2021
- Genomic evidence for reinfection with SARS-CoV-2: a case studyThe Lancet Infectious Diseases, 2021
- Seasonal coronavirus protective immunity is short-lastingNature Medicine, 2020
- Substantial underestimation of SARS-CoV-2 infection in the United StatesNature Communications, 2020
- Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection by a Phylogenetically Distinct StrainClinical Infectious Diseases, 2020
- Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome SequencingClinical Infectious Diseases, 2020
- Duration of Antibody Responses after Severe Acute Respiratory SyndromeEmerging Infectious Diseases, 2007